Sales Of Leukemia Drug Suspended

NEW YORK (October 31, 2013) Ariad Pharmaceuticals says it is suspending sales of its leukemia drug Iclusig because of concerns that patients could suffer from blood clots.

The Cambridge, Mass., company said the U.S. Food and Drug Administration asked it to stop marketing the drug Wednesday afternoon.

The company said Thursday it is negotiating with the FDA about changes to prescribing information and new ways to manage the risks associated with Iclusig.

Ariad said it wants to resume marketing the drug.

In December the FDA approved Iclusig as a treatment for two rare types of leukemia.

KWTX-TV News 10 6700 American Plaza Waco, Texas 76712 (254) 776-1330 Fax (254) 751-1088
Copyright © 2002-2016 - Designed by Gray Digital Media - Powered by Clickability 230059311 -
Gray Television, Inc.